Residency · Residency · Neurosurgery
Low-Grade Gliomas: Diagnosis and Management
Overview
Low-grade gliomas (LGGs) encompass WHO grade 2 diffuse gliomas, including diffuse astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas (the latter largely eliminated in the 2021 WHO classification). These tumors predominantly affect young adults (25-45 years) and present with seizures in 60-90% of cases. The integration of molecular markers -- particularly IDH mutation and 1p/19q codeletion -- has fundamentally transformed classification, prognostication, and treatment decision-making.
Epidemiology and Presentation
Low-grade gliomas account for approximately 15-20% of all primary brain tumors in adults, with peak incidence in the 3rd-4th decade of life and a male-to-female ratio of approximately 1.2:1. The most common presentation is new-onset seizures, occurring in 60-90% of patients. Other presentations include headache, cognitive or personality changes (especially with frontal tumors), and incidental discovery on imaging performed for other reasons. An important biological feature of LGGs is their inherent tendency toward malignant transformation to higher-grade gliomas over time.
WHO 2021 Classification and Molecular Markers
IDH Mutation
The IDH1 R132H mutation is the most common, found in approximately 90% of IDH-mutant gliomas and detectable by immunohistochemistry. IDH2 mutations account for the remainder and require sequencing for detection. IDH-mutant gliomas carry a significantly better prognosis than IDH-wildtype tumors. Importantly, IDH-wildtype diffuse astrocytomas with molecular features of aggressiveness -- such as TERT promoter mutation, EGFR amplification, or +7/-10 chromosome changes -- are now classified as glioblastoma regardless of their histologic grade.
1p/19q Codeletion
Whole-arm codeletion of chromosomes 1p and 19q defines oligodendroglioma when it occurs in the setting of an IDH mutation. This codeletion results from an unbalanced translocation t(1;19)(q10;p10) and is associated with improved response to chemotherapy (particularly PCV) and better overall survival. It can be detected by FISH, array CGH, or next-generation sequencing.
ATRX and TP53
In an IDH-mutant glioma, the combination of ATRX loss and TP53 mutation defines diffuse astrocytoma. ATRX loss is mutually exclusive with 1p/19q codeletion and is detected by immunohistochemistry, which shows loss of nuclear staining.
Current Molecular Classification (WHO 2021)
Under the current scheme, oligodendroglioma is defined as IDH-mutant with 1p/19q codeletion and can be grade 2 or 3. Astrocytoma, IDH-mutant, can be grade 2, 3, or 4. Glioblastoma is by definition IDH-wildtype and grade 4, even if the histology appears low-grade, provided the molecular markers of aggressiveness are present.
| Entity | IDH Status | 1p/19q | ATRX | WHO Grade | Median OS |
|---|---|---|---|---|---|
| Oligodendroglioma | Mutant | Codeleted | Retained | 2 or 3 | >15-20 years |
| Astrocytoma, IDH-mutant | Mutant | Intact | Lost | 2, 3, or 4 | 10-15 years |
| Glioblastoma | Wildtype | Intact | Variable | 4 | 1.5-2 years |
Imaging
MRI Characteristics
On T1-weighted imaging, LGGs appear as hypointense masses that are typically non-enhancing; the presence of enhancement suggests a higher grade or malignant transformation. On T2 and FLAIR sequences, they appear hyperintense, diffusely infiltrating, and often expanding the cortex. DWI usually shows no restricted diffusion, as restricted diffusion suggests higher cellularity and grade. MR spectroscopy reveals elevated choline, decreased NAA, and elevated myo-inositol, with a 2-hydroxyglutarate peak in IDH-mutant tumors. MR perfusion shows low rCBV, with elevated rCBV suggesting a higher grade. Oligodendrogliomas may show calcification (visible on CT) and cortical involvement. Volumetric FLAIR is used to track the growth rate, and a velocity of diametric expansion (VDE) exceeding 8 mm/year is concerning for malignant progression.
Imaging Surveillance
Serial MRI is obtained every 3-6 months initially, then every 6-12 months once the tumor is stable. Quantitative volumetric measurements are superior to bidimensional measurements for detecting slow growth. Any new enhancement warrants consideration of biopsy or resection.
<image> Axial MRI comparison of low-grade glioma on T1-weighted (hypointense, non-enhancing), T2-weighted (hyperintense), and FLAIR (hyperintense with clear delineation from surrounding brain) sequences. A left frontal insular diffuse glioma is shown infiltrating the cortex and subcortical white matter without mass effect or contrast enhancement. Clean radiological teaching illustration with labeled sequences. </image>
Surgical Management
Indications for Surgery
Surgery is indicated for tissue diagnosis and molecular characterization, symptomatic mass effect or medically refractory seizures, and evidence of radiographic progression on serial imaging. There is an increasing consensus favoring early maximal safe resection rather than watchful waiting.
The Extent of Resection Debate
Multiple retrospective studies demonstrate a survival benefit with greater extent of resection (EOR). Supratotal resection, meaning resection beyond the FLAIR abnormality, is emerging as a concept associated with delayed malignant transformation. Key studies supporting aggressive resection include Smith et al. (2008), who showed EOR greater than 90% was associated with improved 5-year overall survival; Jakola et al. (2012), who demonstrated that early surgery outperformed watchful waiting; and Duffau and Taillandier (2015), who advocated for early maximal resection using awake mapping. Functional boundaries must be respected, and resection near eloquent cortex (motor, language, visual) requires intraoperative mapping. EOR is assessed on postoperative MRI obtained within 48 hours using volumetric FLAIR.
Surgical Techniques for Optimization
Awake craniotomy with cortical and subcortical stimulation mapping is used for tumors near or within eloquent areas. Intraoperative MRI (iMRI) allows real-time assessment of EOR. 5-ALA fluorescence is less reliable in LGG than in high-grade gliomas but may show faint fluorescence. Intraoperative ultrasound aids in tumor localization, and neuronavigation with DTI tractography overlay assists in white matter tract preservation.
Functional Outcomes
Supramarginal resection is safe when guided by functional mapping. Cortical plasticity in LGG patients allows for staged surgical approaches, and postoperative deficits are often transient when functional boundaries are respected.
<image> Intraoperative photograph of an awake craniotomy for a left insular low-grade glioma showing the exposed cortical surface with numbered tags marking eloquent cortical sites identified by direct electrical stimulation (language arrest, motor responses). The tumor boundary is outlined, and subcortical stimulation probes are shown targeting the arcuate fasciculus and corticospinal tract. Neurosurgical operative illustration with labeled structures. </image>
Adjuvant Therapy
Radiation Therapy
The EORTC 22845 trial demonstrated that early radiation therapy (54 Gy) versus RT at progression improved progression-free survival but not overall survival. Standard dosing is 50.4-54 Gy in 28-30 fractions. Higher doses are not beneficial, as the EORTC/NCIC trial showed no benefit above 45 Gy and increased toxicity at 64.8 Gy. Side effects include neurocognitive decline (particularly in older patients), radiation necrosis, and secondary malignancy. The timing of RT remains debated, especially in young patients with complete resection.
Chemotherapy
The PCV regimen consists of procarbazine, CCNU (lomustine), and vincristine. RTOG 9802 showed a significant overall survival benefit with RT plus PCV compared with RT alone in high-risk LGG patients (age 40 or older, or subtotal resection), with median OS of 13.3 years versus 7.8 years. Temozolomide (TMZ) is increasingly used as an alternative to PCV due to better tolerability; the EORTC 22033-26033 trial compared TMZ versus RT alone in high-risk LGG, finding equivalent PFS with molecular subgroup-dependent responses. The ongoing CODEL trial is evaluating RT plus PCV versus RT plus TMZ versus TMZ alone for 1p/19q-codeleted oligodendrogliomas.
Risk Stratification for Adjuvant Therapy
Low-risk patients -- those under 40 years old with complete resection and IDH-mutant, 1p/19q-codeleted tumors -- may be appropriate candidates for observation alone. High-risk patients, including those aged 40 or older with subtotal resection, astrocytoma histology, or progressive disease, should receive RT plus chemotherapy. Molecular markers are increasingly guiding therapy selection.
Prognosis
IDH-mutant, 1p/19q-codeleted oligodendrogliomas carry a median overall survival exceeding 15-20 years. IDH-mutant astrocytomas have a median OS of 10-15 years. IDH-wildtype tumors, now classified as GBM, have a median OS of only 1.5-2 years. Factors associated with better prognosis include young age, IDH mutation, 1p/19q codeletion, greater extent of resection, frontal location, seizure presentation, and higher Karnofsky Performance Status.
Clinical Pearls
IDH mutation status is the single most important prognostic marker in diffuse gliomas; if immunohistochemistry for IDH1 R132H is negative in patients under 55 years, IDH status should always be confirmed with sequencing. An IDH-wildtype grade 2 astrocytoma with TERT promoter mutation, EGFR amplification, or +7/-10 is molecularly a glioblastoma and should be managed accordingly. Seizure control often improves dramatically after surgery, with gross total resection achieving seizure freedom (Engel Class I) in 60-80% of LGG patients with epilepsy. The concept of the "oncological window" supports early resection: because LGGs inevitably transform to a higher grade, early maximal resection extends the time before malignant transformation. The volumetric growth rate on serial FLAIR MRI is the best imaging biomarker for malignant transformation risk. Insular gliomas represent a particular surgical challenge, and the Berger-Sanai classification guides resectability based on insular zone involvement.
<image> Flowchart diagram showing the WHO 2021 molecular classification of diffuse gliomas. Starting from a diffuse glioma diagnosis, branching based on IDH mutation status (mutant vs. wildtype), then IDH-mutant tumors branching based on 1p/19q codeletion status (codeleted = oligodendroglioma, non-codeleted with ATRX loss = astrocytoma). IDH-wildtype pathway leads to glioblastoma if molecular criteria are met. Grading criteria for each entity are shown. Clean diagram with color-coded pathways. </image>
References
- Louis DN, et al. "The 2021 WHO Classification of Tumors of the Central Nervous System." Neuro-Oncology. 2021;23(8):1231-1251.
- van den Bent MJ, et al. "EORTC 22845: Low-Dose RT versus Observation after First Biopsy or Resection of Low-Grade Glioma." Lancet. 2005;366(9488):985-990.
- Buckner JC, et al. "RTOG 9802: Radiation Plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma." NEJM. 2016;374(14):1344-1355.
- Smith JS, et al. "Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas." JCO. 2008;26(8):1338-1345.
- Jakola AS, et al. "Comparison of a Strategy Favoring Early Surgical Resection vs. a Strategy Favoring Watchful Waiting in Low-Grade Gliomas." JAMA. 2012;308(18):1881-1888.
